Takeda Pharmaceutical has acquired rights to a drug called elritercept from Keros Therapeutics for $200 million, excluding rights in China. Elritercept is being studied for use in treating blood cancers like myelodysplastic syndrome and myelofibrosis, which lead to anemia. This drug could compete with Bristol Myers Squibb’s Reblozyl, which generated $1.2 billion in revenue in 2023. Keros believes elritercept could help a broader range of MDS patients and potentially be used in other conditions with low blood cell levels. Preliminary data shows promise, and Phase 3 trials are set to begin soon. Takeda intends to further develop elritercept for hematologic disorders.
Source link
Takeda Pays $200M for Keros Therapeutics Drug With Potential in Blood Cancers and Beyond
